Skip to content
Search

Latest Stories

ABPI outlines top priorities for Labour's first 100 days in office

ABPI outlines top priorities for Labour's first 100 days in office

ABPI calls on Labour to urgently appoint a new Chair and Chief Executive to the Medicines and Healthcare products Regulatory Agency (MHRA)

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office.

Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA).


Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay.

Other measures the ABPI wants Labour to prioritise include:

  • Rapidly passing outstanding UK clinical trials legislation to enhance the UK’s attractiveness for inward investment, including into research within the NHS.
  • Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.
  • Supporting the National Institute for Health and Care Excellence (NICE) to rapidly review the ‘severity modifier’ used in medicine appraisals.
  • Re-establishing a cross-government and industry working group to examine progress in implementing vaccination-related policy.
  • Reviewing and responingd to outstanding recommendations for the National Immunisation Programme made by the Joint Committee on Vaccination & Immunisation.

Responding to the new health secretary’s commitment to boosting the economy through the life sciences sector, Richard Torbett, Chief Executive of ABPI, said: “Wes Streeting is right to think about the health system as more than just a public service.

“It is an intrinsic part of our national economy - as an employer, as a driver and adopter of new innovations, and as a place to do cutting-edge research and discovery.”

He emphasised that with the right outlook, the health system could become an “active partner” in life science innovation and discovery.

“It can do more to prevent ill health, through the use of new vaccines and preventative medicines, while also getting people healthy and back to work by removing persistent inequality of access to the most effective treatments,” he added.

Addressing the Tony Blair Institute Future of Britain Conference on Monday, Wes Streeting, Secretary of State for Health and Social Care, said:

“One of the things I've said to my department and to the NHS is we need to rethink our role in government and in our country at large.

“This is no longer simply a public services department. This is an economic growth department, and the health of the nation and the health of the economy are inextricably linked.”

“If we can marry our health and social care system with the incredible life sciences and med tech ecosystem we have in this country, we can be a powerhouse for the life sciences and med tech revolution here in this country and in the world. And that is an economic growth mission.”

During its election campaign, Labour has identified the UK’s life sciences sector as a critical partner for its plans to deliver positive change and economic growth.

Torbett earlier said that a strong industry-government partnership will be vital for continued discovery of breakthrough medical innovation in the UK, ensuring NHS patients are among the earliest beneficiaries of cutting-edge medicines and vaccines worldwide.

He said: “The new government now needs to hit the ground running and rapidly set out a clear, detailed plan for what the government will do in the coming weeks and years to address persistent inequalities in access to medicines and vaccines as well as unlock our sector's true growth potential.”

ABPI’s ‘Manifesto for Investment, Health, and Growth’ outlines a strategy aimed at improving healthcare and equity for NHS patients, enhancing patient access to new medicines through clinical trials, generating additional manufacturing jobs and value within the UK, and creating more highly skilled, well-paid jobs in all parts of the country.

More For You

 RPS honours Professor Tony Avery OBE for excellence in prescribing safety and patient care

Professor Tony Avery OBE

Pic credit: RPS

Professor Tony Avery OBE awarded RPS Honorary Fellowship

The Royal Pharmaceutical Society (RPS) Assembly has awarded an Honorary Fellowship to Professor Tony Avery OBE in recognition of his outstanding contribution to prescribing safety and patient care.

The Honorary Fellowship is given to those who are not eligible for membership of the Society but have either attained a distinction in a particular aspect or aspects of pharmacy, made a distinctive contribution to pharmacy or the RPS, distinguished themselves in any branches of knowledge referred to in the objects of the Society or achieved eminence in public life.

Keep ReadingShow less
US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less